Navigation Links
Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
Date:11/6/2008

s)

September 30, December 31,

2008 2007

(unaudited)

Assets

Current assets:

Cash and cash equivalents $21,809 $50,624

Short-term securities 75,321 34,836

Accounts receivable, net of

allowance for doubtful accounts 16,362 9,013

Deferred tax asset 6,380 -

Other current assets 1,280 1,409

Total current assets 121,152 95,882

Property and equipment, net 9,555 1,950

Long-term securities 3,775 -

Deferred tax asset 3,668 -

Restricted cash 360 -

Other long-term assets 179 -

Total assets $138,689 $97,832

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued

expenses $7,561 $4,238

Accrued compensation 4,939 2,496

Income tax payable 2,853 74

Deferred revenues 58 95

Deferred rent 248 -

Total current liabilities 15,659 6,903

Deferred rent, net of current portion 1,510 324

Commitments and contingencies

Stockholders' equity:

Pref
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 1The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 2New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 1New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 2Testosterone Therapy May Help Men With Heart Failure 55194 1Testosterone Therapy May Help Men With Heart Failure 55194 2Testosterone Therapy May Help Men With Heart Failure 55194 3